ClinicalTrials.gg

Program

ADX-038

A development code. Also written as “ADX-038 Dose Level 2” and “ADX-038 Dose Level 1”.

Its studies are mostly in Glomerulonephritis, IGA · Geographic Atrophy · Hemoglobinuria, Paroxysmal, led by ADARx Pharmaceuticals.

Furthest: phase 2, since May 17, 20234 company-led studies, 4 open or runningNext primary completion: Mar 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ADARx Pharmaceuticals44 open or runningphase 2since May 17, 2023May 17, 2023Mar 31, 2028phase 2 · NCT05876312

Also a collaborator on its studies: novotech-australia-pty-limited.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 17, 2023First study: phase 2 study in Hemoglobinuria, ParoxysmalFirst studyNCT05876312 · 50 planned · Australia, United Kingdom
  2. May 22, 20252 phase 2 studiesNCT06990269, NCT06989359
  3. Feb 27, 2026Phase 2 study in Glomerulonephritis, IGANCT07522099 · 30 planned · China

Ahead

  1. Mar 31, 2028Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT05876312
  2. Jul 10, 2028Primary completion: phase 2 study in Glomerulonephritis, IGANCT07522099
  3. Dec 31, 2028Primary completion: phase 2 study in Glomerulonephritis, IGANCT06989359
  4. Feb 28, 2030Primary completion: phase 2 study in Geographic Atrophy Secondary to Age-related Macular DegenerationNCT06990269

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07522099Glomerulonephritis, IGA · China2RecruitingJul 10, 202830
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration · United States, Australia, Austria and more2RecruitingFeb 28, 2030240
NCT06989359Glomerulonephritis, IGA · United States, Australia, Hong Kong and more2RecruitingDec 31, 202845
NCT05876312Hemoglobinuria, Paroxysmal · Australia, United Kingdom2RecruitingMar 31, 202850

How it is read

Names in the registry

  • “ADX-038”, 3 entries
  • “ADX-038 Dose Level 2”, 1 entry
  • “ADX-038 Dose Level 1”, 1 entry

Codes read as this program: ADX038.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.